Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis

Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis

June 9, 2014

– Study met primary efficacy endpoint with statistical significance after 24 weeks of treatment –

– Safety data are supportive of differentiated product profile –

–   Investor conference call and webcast today at 5:00 p.m. EDT (2:00 p.m. PDT) –

Agios Pharmaceuticals Initiates Multiple Ascending Dose Trial in Healthy Volunteers of AG-348 for the Potential Treatment of PK Deficiency, a Rare, Hemolytic Anemia

Agios Pharmaceuticals Initiates Multiple Ascending Dose Trial in Healthy Volunteers of AG-348 for the Potential Treatment of PK Deficiency, a Rare, Hemolytic Anemia

June 9, 2014

 Initial Safety and Pharmacokinetic Findings From Single Ascending Dose Trial Support Early Advancement

Seres Health Closes Series B Financing and Enters into a Research Agreement with Mayo Clinic

Seres Health Closes Series B Financing and Enters into a Research Agreement with Mayo Clinic

June 9, 2014

CAMBRIDGE, Mass., June 9, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel products to treat a host of disease conditions based on scientific findings related to the human microbiome, announced today that it has closed its $10 million Series B financing that included existing investors Flagship Ventures and Enso Ventures, and included new investors, Mayo Clinic, Alexandria Venture Investments, and several private investors. The company has also entered into an exclusive research collaboration with the Mayo Clinic.

Flagship Ventures Commences Its Sixth VentureLabs™ Fellowship Program Focused On Entrepreneurial Innovation

Flagship Ventures Commences Its Sixth VentureLabs™ Fellowship Program Focused On Entrepreneurial Innovation

June 5, 2014

CAMBRIDGE, Mass., June 5, 2014 /PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on healthcare and sustainability, announced the start of its sixth VentureLabs™ Fellowship Program, a unique opportunity for top graduate and post-graduate students to learn VentureLabs' approach to company conception, innovation and entrepreneuring.

T2 Biosystems Submits 510(k) Application to the FDA for Review of T2Dx and T2Candida

T2 Biosystems Submits 510(k) Application to the FDA for Review of T2Dx and T2Candida

June 3, 2014

LEXINGTON, Mass.--()--T2 Biosystems today announced that it has filed a 510(k) premarket submission for T2Dx and T2Candida with the U.S. Food and Drug Administration (FDA).

Seres Health Appoints Former Merck Senior Executive, Roger J. Pomerantz, M.D., F.A.C.P., as Chief Executive Officer and Chairman

Seres Health Appoints Former Merck Senior Executive, Roger J. Pomerantz, M.D., F.A.C.P., as Chief Executive Officer and Chairman

June 2, 2014

CAMBRIDGE, Mass., June 2, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel products to treat a host of disease conditions based on scientific findings related to the human microbiome, announced today that it has appointed Roger J. Pomerantz, M.D., F.A.C.P. as its President and Chief Executive Officer. Dr. Pomerantz will also remain as Chairman of the Board of Directors of Seres, where he has served since November of 2013. Dr.

Novomer Announces Commercial Launch of Converge® Polyols for Broad Use in Polyurethanes Industry

Novomer Announces Commercial Launch of Converge® Polyols for Broad Use in Polyurethanes Industry

May 29, 2014

Company ramps up production of unique CO2-based polyols at multi-thousand-ton plant in Houston.

Quanterix Selected as a Red Herring Top 100 North America Winner

Quanterix Selected as a Red Herring Top 100 North America Winner

May 29, 2014

LEXINGTON, Mass., May 29, 2014 (BUSINESS WIRE) -- Quanterix , a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced it has been selected as a winner for

Charles Rowland Elected to BIND Therapeutics Board of Directors

Charles Rowland Elected to BIND Therapeutics Board of Directors

May 28, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced that at BIND’s annual meeting of stockholders held today the company’s stockholders elected Mr. Charles A. Rowland, Jr., CPA, most recently the Vice President and Chief Financial Officer of ViroPharma Incorporated, to its Board of Directors.

Joule Names Tom Einar Jensen Head of Corporate Development

Joule Names Tom Einar Jensen Head of Corporate Development

May 21, 2014

Bedford, MA – May 21, 2014 – Joule today announced the appointment of Tom Einar Jensen as Executive Vice President, Head of Corporate Development, providing leadership in the areas of investment, business development, strategy, communication and commercialization.